Biotech

pharmBD is a boutique-style advisory firm in lifescience corporate development.
Helene Moore is the Chair of the Lifesciences investing group at Anges Quebec and also serves on the Investment Committee of Seido Capital.

- Early stage biotech interested by Angel investing. Medtechs and Digital health with clear IP and data Moat.
Anges Quebec does not (or very rarely) lead lifesciences rounds.

Biotech

Raymond James Ltd., the Canadian arm of Raymond James Financial, Inc. (NYSE: RJF), is Canada's
largest independent financial services firm, providing comprehensive wealth management and
capital markets services to individuals and institutions for 25 years. With C$100 billion in assets
under administration, more than 520 independent advisors and 2,000 associates across 170
branches and offices, we are dedicated to putting clients first, thinking long-term, acting with
integrity, and valuing independence.

Series B+ (18-24 months from public listing) or publicly traded healthcare, medical technology, and biotechnology companies.

Other

Work with Life Sciences companies and Investors, but providing Venture Debt and Banking services.

Have some seed funding.

Digital Health

Early stage life sciences health technology investors focused on chronic disease management. Conditions of focus: diabetes, CV disease, metabolic disorders, neurotech, mobility

Interest in relationship development; Fund I fully deployed.

Biotech

Roy Family Office is a Singke Family Office which operates in Toronto, ON, Canada. We are involved in Philanthropy, cash generating M & A, diversified investments for infrastructural growth and advancement (industry agnostic)

Founder has to be fiscally responsible with an extensive background in their field.

Biotech

Toronto-based venture capital that invest in technology and healthcare. We invest in late preclinical (IND enabling studies) or early clinical phase companies. We are modality, therapeutic and geographically agnostic in terms of biotechs.

Late preclinical or early clinical phase companies

Pharma

I am an angel investor, operator in Pharma and in Tech, having exited 8x to start ThinkrBelle 2023. We are backed by a team of 7 associates with 130+ years of collective global, US and Canadian biopharma experience. We are also well-versed in the digital ecosystem, work with digital health, digital companions, med devices, and AI-enabled ventures building solutions pharma will want.
We help founders position, pressure-test, and land enterprise opportunities — turning traction into real deals (and avoiding pilotitis).

HealthTech, MedDevice and Biotech with a road to Pharma looking to land a paid partnership that can generate revenue.

MedTech

Investor in early state companies that have IP out of UofT and affiliated academic institutions

Medical device, digital health and have institutional IP from Toronto hospitals and academics

Biotech

The University of Waterloo launched Velocity Incubator in 2008 and over the last 15 years we’ve helped 450+ alumni companies create USD 26B+ in equity value.
Velocity Fund is the next step in Velocity’s evolution. It is the fund that we wanted to work with when we were founders. We invest at the pre-seed and seed rounds into companies led by ambitious founders across software, deep tech, and health tech. We move fast, offer no-nonsense advice, and connect you to a world-class network of alumni founders.

Pre-seed / seed stage companies who have
- Market size / opportunity is low risk
- Initial proof points of customer love (no matter how small)
- Founder-market fit

Life Science Tools / Research Tech

Velocity I. R. play a crucial role in bridging the gap between a company and its investors. We integrate finance, communications, marketing and securities law compliance to manage investor relations effectively. We prioritize clear & transparent communication to build trust with investors. Organizing and managing investor meetings, earnings call(s) and one on one meetings with investors.

revenue generating

Pharma

Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies.

Developing a therapeutic product for an unmet need with intent to raise capital in excess of $10M in the next 6 months

Biotech

Venture Partner for funds
Entrepreneur in Residence for Investissement Québec

Private companies.
Major focus in biotechnology. Opportunistic interest in other sectors, enabling technologies, medtech and diagnostic

Digital Health

WELLSTAR is the leading provider of healthcare-focused technology solutions. WELLSTAR’s comprehensive range of products and solutions are designed to streamline care delivery, integrate fragmented healthcare systems more seamlessly, reduce provider burnout, and improve patient healthcare experiences and outcomes.

- Digital health companies (for example: AI Scirbe, AI Triage, EMR, Billing software, Clinical decision support software)

Diagnostics

We are the corporate venture arm of Werfen, a worldwide leader in Specialized Diagnostics.
We invest in early-stage start-ups close to market entry, or early scale-ups.
We combine the agility of a VC with an unique understanding of the diagnostics sector, empowering startups with strategic insight, global reach, and deep diagnostics know-how.

Investing globally in diagnostics start-ups, as well as digital solutions and life science tools disrupting the diagnostics arena, at Seed to series B.

MedTech

Wittington Ventures is a $500M multi-stage investment platform that backs transformative companies across the consumer, commerce, healthcare, and climate sectors.

Backed by Wittington Investments – the holding company of the Weston group of companies that includes Loblaw, Shoppers Drug Mart, and Choice Properties – the firm leverages its proprietary industry access, philanthropic research insights, and long-term capital to support founders throughout their growth journey.

We provide immense value to our founders and their investors by building trusted relationships with our portfolio companies, where we gain an in-depth understanding of who they are and how they are positioned to take advantage of market growth.

Pre-seed/Seed Deeptech Healthcare

Other

The Wittington Ventures' Innovation Fund is a 100M catalytic investment platform backing early-stage climate and healthcare technologies, with a focus on supporting Canadian research translation and commercialization. We work closely across the broader Wittington platform—including operating companies and the Weston Family Foundation—to help promising innovations move from lab to real-world impact.

Pre Series A - ideally in subject areas related to neuro and the microbiome.